YM022|cas:145084-28-2|西域试剂

YM022,99.67%

产品编号：Bellancom-103355| CAS NO：145084-28-2| 分子式：C₃₂H₂₈N₄O₃| 分子量：516.59

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-103355		￥5500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

YM022

产品介绍

YM022 是一种高效，选择性和口服活性胃泌素/胆囊收缩素(CCK)-B 受体 (CCK-BR) 拮抗剂。 YM022 显示CCK-B 和 CCK-A 受体的 K_i 值分别为 68 pM 和 63 nM。 YM022 在体内可以抑制胃泌素诱导的胃酸分泌和组氨酸脱羧酶的活化。

生物活性

YM022 is a highly potent, selective and orally active gastrin/cholecystokinin (CCK)-B receptor (CCK-BR) antagonist. YM022 shows the K_i values of 68 pM and 63 nM for CCK-B and CCK-A receptor, respectively. YM022 can inhibit gastrin-induced gastric acid secretion and histidine decarboxylase activation in vivo.

体外研究

YM022 inhibits binding to canine pancreas CCK-A receptor in a dose-dependent manner, with an IC₅₀ value for [³H]devazepide binding of 136 nM.
YM022 inhibits the binding of [¹²⁵I]CCK-8 to canine cloned gastrin/CCK-B receptor in a dose-dependent manner, with an IC₅₀ value for [¹²⁵I]CCK-8 binding of 0.73 nM.
Selectivity [ratio of (IC₅₀ for gastrin/CCK-B receptor)/(IC₅₀for CCK-A receptor)] of YM022 is 186.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

YM022 (intravenous injection; 0.01-1 μM/kg) dose-dependently inhibits pentagastrin- and peptone meal-induced acid secretion with ED₅₀ values of 0.0261 and 0.0654 μmol/kg, respectively, without affecting histamine- or methacholine-induced acid secretion.
YM022 (subcutaneous injection; 300 μmol/kg; single dose) lowers the oxyntic mucosal HDC activity and raises the serum gastrin concentration in a dose-dependent manner (measured 24 h after dosage). Maximum enzyme inhibition is achieved at a dose of 300 μmol/kg for YM022 and the inhibition of HDC lasts for 4 weeks. At sacrifice, drug residues can be seen at the injection site for as long as 4 (YM022) weeks after injection in rat.
YM022 is suspended in 2% Methocel for oral ingestion and in PEG300 for subcutaneous injection.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Rat
Dosage:	300 μmol/kg
Administration:	Subcutaneous injection; 300 μmol/kg; single dose
Result:	Suppressed the ECL cell activity for at least 4 as manifested in greatly reduced HDC activity, greatly elevated serum gastrin level.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Rat
Dosage:	300 μmol/kg
Administration:	Subcutaneous injection; 300 μmol/kg; single dose
Result:	Suppressed the ECL cell activity for at least 4 as manifested in greatly reduced HDC activity, greatly elevated serum gastrin level.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (193.58 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.9358 mL	9.6789 mL	19.3577 mL
5 mM	0.3872 mL	1.9358 mL	3.8715 mL
10 mM	0.1936 mL	0.9679 mL	1.9358 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (4.84 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (4.84 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。